Precipio, Inc. terminates its ATM instrument, citing improved financial position and confidence in capital raises.
Quiver AI Summary
Precipio, Inc., a specialty cancer diagnostics company, announced the termination of its At-The-Market (ATM) instrument with Alliance Global Partners, signaling its improved financial stability and reduced reliance on external capital raises. CEO Ilan Danieli highlighted that the company has eliminated negative cash flow and increased its cash reserves, allowing them to focus on creating shareholder value. Precipio is dedicated to addressing cancer misdiagnoses through innovative diagnostic products and services that enhance accuracy and workflow in laboratories. For more information, the company encourages stakeholders to visit its website and follow its social media channels. The press release also contains forward-looking statements regarding the company's future plans and performance.
Potential Positives
- Termination of the ATM facility indicates a stronger financial position and reduced reliance on external capital for future growth.
- The elimination of negative cash flow from operations demonstrates improved operational efficiency and financial health.
- Increased cash balance enhances confidence in the company's ability to support its activities without needing additional funding through the ATM instrument.
- Commitment from management to create shareholder value reflects a positive outlook on corporate governance and future performance.
Potential Negatives
- The termination of the ATM instrument may indicate that the company lacks alternative capital-raising strategies, raising concerns about future financial flexibility.
- The reliance on forward-looking statements could lead to speculative interpretations, increasing investor uncertainty regarding the company's actual performance and growth prospects.
- The focus on improving cash flow and increasing cash reserves raises questions about prior financial difficulties and the company's overall stability.
FAQ
Why did Precipio terminate its ATM agreement with AGP?
Precipio terminated the ATM agreement as it is in a stronger financial position and no longer needs this capital-raising tool.
How has Precipio's financial position improved?
The company has eliminated negative cash flow from operations and increased its cash balance, enhancing its overall financial stability.
What is Precipio's mission in cancer diagnostics?
Precipio aims to address cancer misdiagnoses by developing diagnostic products and services that improve accuracy and patient outcomes.
Where can investors find more information about Precipio?
Investors can visit Precipio's website at https://www.precipiodx.com/ for company disclosures and updates.
Are there any forward-looking statements in the press release?
Yes, the press release contains forward-looking statements regarding financial performance, which involve risks and uncertainties.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRPO Insider Trading Activity
$PRPO insiders have traded $PRPO stock on the open market 9 times in the past 6 months. Of those trades, 9 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PRPO stock by insiders over the last 6 months:
- RICHARD A SANDBERG has made 8 purchases buying 15,000 shares for an estimated $135,981 and 0 sales.
- AHMED ZAKI SABET (Chief Operating Officer) purchased 79 shares for an estimated $473
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PRPO Hedge Fund Activity
We have seen 5 institutional investors add shares of $PRPO stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC removed 10,700 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $118,127
- AMH EQUITY LTD removed 10,404 shares (-27.2%) from their portfolio in Q2 2025, for an estimated $114,860
- UBS GROUP AG added 675 shares (+68.9%) to their portfolio in Q2 2025, for an estimated $7,451
- TOWER RESEARCH CAPITAL LLC (TRC) removed 656 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $7,242
- GEODE CAPITAL MANAGEMENT, LLC added 122 shares (+0.8%) to their portfolio in Q2 2025, for an estimated $1,346
- OSAIC HOLDINGS, INC. added 37 shares (+50.7%) to their portfolio in Q2 2025, for an estimated $408
- ALLWORTH FINANCIAL LP added 3 shares (+inf%) to their portfolio in Q2 2025, for an estimated $33
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners (AGP).
“Our Company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations, and our recent increases of our cash balance, we now have confidence that we no longer have to rely on a tool like this for capital raises for the Company,” said Ilan Danieli, Precipio’s CEO. “Management is committed to creating shareholder value, and this termination is one more step in that direction.”
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) ( @PrecipioDx ) and LinkedIn (Precipio) and on Facebook . Investors and others should note that we communicate with our investors and the public using our company website ( https://www.precipiodx.com ), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.